Three members of an independent FDA advisory panel say they received advanced information ahead...

|By:, SA News Editor

Three members of an independent FDA advisory panel say they received advanced information ahead of U.S. regulators in May 2010 regarding the rejection of a drug from InterMune (ITMN -2.5%), which is now at the heart of a trading investigation of SAC Capital. ITMN’s shares fell 5.4% the day before the company announced the rejection. However, others at the FDA were also aware of the rejection too, and there’s no evidence the 11 panelists did anything wrong.